<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.5281/zenodo.14770763</article-id>
      <article-id pub-id-type="publisher-id">AJPTR146007</article-id>
      <title-group>
        <article-title>Analytical method development and validation of Niraparib and Abiraterone using RP-HPLC method by using QbD method</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>B</surname>
            <given-names>Mounica</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kommineni</surname>
            <given-names>Vinutha</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>P</surname>
            <given-names>Sreedevi</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2024-12-01">
        <month>12</month>
        <day>01</day>
        <year>2024</year>
      </pub-date>
      <volume>14</volume>
      <issue>6</issue>
      <abstract>
        <p>A robust RP-HPLC technique was set up for the estimation of Abiraterone &amp; Niraparib. SST parameters, including resolution, theoretical plates, &amp; tailing factor, were within acceptable boundaries, ensuring the technique&apos;s reliability. technique verification followed ICH rules, demonstrating high assay accuracy with recoveries within 98-102%. The linearity scale was 10-50 µg per ml for Abiraterone &amp; 2-10 µg per ml for Niraparib, with R2 of 0.999. Precision, ID precision, &amp; robustness tests confirmed the technique&apos;s consistency across different conditions. LOD &amp; LOQ were established, showcasing the technique&apos;s sensitivity. This verified RP-HPLC technique is suitable for regular analysis of Abiraterone &amp; Niraparib in l formulations.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Niraparib</kwd>
        <kwd>Abiraterone</kwd>
        <kwd>QbD</kwd>
        <kwd>RP HPLC. </kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
